Paper Details

  1. Home
  2. Paper Details

Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Felodipine was found to be effective in lowering blood pressure in hypertensive patients already on beta-blockers. Both initial blood pressure level and plasma felodipine concentrations were predictors of the response, while age was not.
Paper Details　
Original Abstract of the Article :
1. The antihypertensive efficacy of two different doses of the calcium antagonist felodipine was evaluated in patients with hypertension persisting despite beta-adrenoceptor blocker therapy. Following a single-blind placebo period of 4 weeks, patients were randomized to placebo (n = 36), felodipine ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2125.1988.tb05293.x

データ提供：米国国立医学図書館（NLM）

Antihypertensive Efficacy of the Calcium-Antagonist Felodipine in Patients with Persisting Hypertension on Beta-Adrenoceptor Blocker Therapy

Hypertension, a condition characterized by high blood pressure, is like a desert sandstorm that can erode the delicate walls of our blood vessels. This research investigates the effectiveness of felodipine, a calcium antagonist, in treating hypertension in patients who are already taking beta-adrenoceptor blockers.

Felodipine: An Effective Treatment Option for Hypertension

The study found that felodipine effectively lowered blood pressure in patients with persistent hypertension, even when they were already taking beta-adrenoceptor blockers. This is like using a combination of techniques to manage a desert sandstorm, working together to protect the oasis from damage. The research suggests that felodipine can be a valuable addition to the treatment of hypertension, offering a more comprehensive approach to blood pressure management.

Managing Hypertension

This study underscores the importance of finding the right combination of treatments for managing hypertension. It's a reminder that even in the challenging desert of hypertension, we can find effective solutions to protect our cardiovascular health.

Dr.Camel's Conclusion

This study emphasizes the importance of finding the right combination of treatments for managing hypertension. It's like navigating a desert landscape, finding the right path to manage the sandstorms and protect the oasis. This research demonstrates that felodipine, when used in conjunction with other treatments, can be an effective tool for controlling hypertension. It's a reminder that even in the unpredictable desert of cardiovascular health, there are solutions to ensure a healthier future.
Date :
  1. Date Completed 1989-02-21
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

2905154

DOI: Digital Object Identifier

10.1111/j.1365-2125.1988.tb05293.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.